Related Experiment Videos
[Resistance to cytostatic agents in patients with refractory multiple myeloma and possible ways to control it]
1II. interní klinika Fakultní nemocnice, Brno.
Abstract:
At present several mechanisms responsible for the resistance of tumour cells to cytostatics are known. Most explored is the resistance conditioned by glycoprotein-P. Under laboratory conditions it proved possible to inhibit the resistance caused by glycoprotein-P by many substances which, however, on clinical administration have serious adverse side-effects. In practice verapamil was used, its effect was most marked in haematological malignant diseases. Side-effects of verapamil, however, do not permit to attain the necessary concentration. Obviously better results will be achieved by cyclosporin A which can attain a concentration in the organism which is necessary to inhibit glycoprotein-P without serious undesirable consequences. In the submitted paper the author reviews clinical studies concerned with possible inhibition of glycoprotein-P in patients with refractory myeloma.
Insights
Cyclosporin A effectively inhibits glycoprotein-P, a key factor in chemotherapy resistance, offering a safer alternative to verapamil for treating refractory myeloma.
Area of Science:
- Oncology
- Pharmacology
Background:
- Tumor cells develop resistance to chemotherapy through various mechanisms.
- Glycoprotein-P-mediated resistance is a significant challenge in cancer treatment.
- Existing inhibitors like verapamil have limitations due to severe side effects.
Purpose of the Study:
- To review clinical studies on inhibiting glycoprotein-P in refractory myeloma patients.
- To evaluate cyclosporin A as a potential agent for overcoming chemotherapy resistance.
- To compare the efficacy and safety of cyclosporin A versus verapamil.
Main Methods:
- Review of clinical studies involving glycoprotein-P inhibition.
- Analysis of data on cyclosporin A and verapamil in cancer treatment.
- Focus on patients with refractory myeloma.
Main Results:
- Cyclosporin A can achieve therapeutic concentrations necessary to inhibit glycoprotein-P.
- Cyclosporin A demonstrates a favorable safety profile compared to verapamil.
- Potential for improved outcomes in refractory myeloma patients.
Conclusions:
- Cyclosporin A shows promise for inhibiting glycoprotein-P and overcoming chemotherapy resistance.
- Its safety profile makes it a viable option for clinical application in refractory myeloma.
- Further clinical investigation is warranted to confirm efficacy.